Outset Medical, Inc. (OM)
NASDAQ: OM · Real-Time Price · USD
16.29
+0.99 (6.47%)
At close: May 12, 2025, 4:00 PM
16.29
0.00 (0.00%)
After-hours: May 12, 2025, 4:05 PM EDT
Outset Medical Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Outset Medical stock have an average target of 29.5, with a low estimate of 14 and a high estimate of 45. The average target predicts an increase of 81.09% from the current stock price of 16.29.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Outset Medical stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $12 → $14 | Hold | Maintains | $12 → $14 | -14.06% | May 8, 2025 |
| RBC Capital | RBC Capital | Hold Reiterates $45 | Hold | Reiterates | $45 | +176.24% | Jan 7, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $90 → $45 | Buy → Hold | Downgrades | $90 → $45 | +176.24% | Aug 8, 2024 |
| TD Cowen | TD Cowen | Strong Buy Maintains $135 → $45 | Strong Buy | Maintains | $135 → $45 | +176.24% | Aug 8, 2024 |
| RBC Capital | RBC Capital | Hold → Buy Upgrades $75 → $90 | Hold → Buy | Upgrades | $75 → $90 | +452.49% | Jun 21, 2024 |
Financial Forecast
Revenue This Year
123.90M
from 113.69M
Increased by 8.98%
Revenue Next Year
139.69M
from 123.90M
Increased by 12.74%
EPS This Year
-3.42
from -36.95
EPS Next Year
-2.95
from -3.42
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 126.8M | 147.0M | 170.0M | ||
| Avg | 123.9M | 139.7M | 156.1M | ||
| Low | 117.6M | 129.9M | 142.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 11.6% | 18.6% | 21.7% | ||
| Avg | 9.0% | 12.7% | 11.7% | ||
| Low | 3.4% | 4.8% | 2.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.47 | -2.25 | -1.50 | ||
| Avg | -3.42 | -2.95 | -2.43 | ||
| Low | -3.88 | -3.80 | -3.42 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.